I just read over the last quarter transcript. I can't say I really have a good feel for this company. In the last few months we have the 'old' antitrust investigation, and a recent quarterly report. A recent loss of business with LabCorp is a negative as well. The last quarter saw margins dip a bit, but they are still healthy. The explanation being newer instrument rollouts which are lower margin. BLUD looks to make its money on higher-margin consumables run on its instruments.Still this is a pretty recession proof business, so I'm inclined to stick with BLUD as a CAPS play, but I don't think I really understand the business well enough to invest for real. So, I have to have a bit of faith that margins will begin to pick up again, but that will likely be a year from now or later.(This will be my caps pitch)
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar